• 대한전자공학회:학술대회논문집
• /
• 대한전자공학회 2008년도 하계종합학술대회
• /
• pp.389-390
• /
• 2008

The dependence of $f_T$ and $f_{max}$ on the unit finger width is measured and analyzed for $0.13{\mu}m$ MOSFETs. The increase of $f_T$ at narrow width is attributed by the parasitic gate-bulk capacitance, and the decrease of $f_T$ at wide width is generated by the reduction of increasing rate of $g_{mo}$. The increase of $f_{max}$ at narrow width is originated from the abrupt reduction of gate resistance due to the non-quasi-static effect. These analysis results will be valuable information for layout optimization to improve $f_T$ and $f_{max}$.

• 생명과학회지
• /
• 제13권1호
• /
• pp.59-66
• /
• 2003

Starter로 사용하기 위하여 $20^{\circ}C$에서 4일간 발효된 돌산 갓김치에서 미생물을 분리하였다. 이를 starter로 접종하여 $4^{\circ}C$와 $10^{\circ}C$에서 50일간 발효시키면서 발효특성, 항산화활성, ACE 저해활성을 조사하였다. 1 X $10^{10}$ CFU/mL의 접종농도에서 적숙기(pH 4.5)에 도달하는 시간이 $4^{\circ}C$에서는 최고 5.6배 이상, $10^{\circ}C$에서는 5배 단축되었다. 총균수는 starter 접종농도가 높을수록 발효초부터 높은 균수를 유지하였다. 항산화활성도 starter 접종농도가 높을수록 전반적으로 골게 나타났고, 1 X $10^{10}$ CFU/mL의 접종농도에서 $4^{\circ}C$와 $10^{\circ}C$ 각각 최대 67%와 75%를 나타내었다. 따라서 단위 시간당 세포의 생성율($lnX_{max}$/$t_{max}$)과 항산화활성($lnX_{max}$/$t_{max}$)은 비례관계를 가지며, 초기 접종농도가 높을수록 단위 시간 당 항산화활성이 높음을 알 수 있었다. ACE 저해활성도starter의 농도가 높을수록 ACE 저해활성도 놀게 나타났다. 즉, 1 X $10^{10}$ CFU/mL의 접종농도에서 $4^{\circ}C$에서는 52%, $10^{\circ}C$에서는 최대 76%를 나타내었다. 파라서 일정시간당 체포의 생성율($lnX_{max}$/$t_{max}$)이 증가할수록 ACE 저해율 ($P_{max}$/$t_{max}$)도 증가하였으며, 초기 접종농도가 높을수록 단 위 시간당 ACE 저해율이 높았다.

• 천문학회보
• /
• 제32권1호
• /
• pp.48.2-48.2
• /
• 2007

• Archives of Pharmacal Research
• /
• 제18권6호
• /
• pp.385-390
• /
• 1995

The analytical methods for the analysis of cyclosporine (CsA), a fluorescence polarization immunoassay (FPIA) and HPLC method, were compared in a pharmacokinetic study of two CsA soft capsule formultaions ($Sandimmun^{\circledR}$; Sandoz, $Implanta^{\circledR}$; Hanmi). Sixteen healthy volunteers completed the study and each subjected single doses ($4{\tiems}100$ mg) of the test and the reference formulations in a two-way crossover design with a one-week drug-free interval between doses. Following each administration, whole blood concentrations of CsA were monitored over a period of 24 hour by both FPIA and HPLC methods. Blood concentrations nad pharmacokinetic parameters determined by either analytical method showed large intersubject variation, with the FPIA data showing relatively higher magnitude of intersubjecte variation than the HPLC data. The blood concentrations determined by FPIA were 1.1-1.3 times higher than those determined by HPLC. There were strong and significant correlations between the two methods (r>0.83 : p<0.0001). Intersubuject variation for the $AUC_{inf}{\;}and{\;}AUC_{24hr}$ of the test formulation was slightly reduced without statistical significance (paried -t test : p>0.05 $t_{max}$ was earlier nad $C_{max}$ was slightly lower for the test formulation, $AUC_{24h}, {\;}C_{max}, {\;}T_{max}$ and MRT determined separately from the data obtained by the two methods for the two formulations were examined by analyses of variance (ANOVA) for the bioequivalency evaluation. Results of ANOVA and confidence limits of terst/reference ratios of $AUC_{24th}$, $C_{max}$, $t_{max}$ and MRT, and statistical tests indicated the bioequivalence of the two formulations (i.e., test/reference ratio was within $100{\times}20%$) except for $C_{max}$ and $t_{max}$. The mean of tmax also showed 11.1% and 9.3% differences but the detection limit were 29.2% and 29.6% as determined by FPIA and HPLC resepctively. This experiments suggest that the data yielded for the two formulations demonstrated that they were bioequivalent.

• Archives of Pharmacal Research
• /
• 제18권4호
• /
• pp.237-242
• /
• 1995

For the vioequivalence study of two ceftriaxone injection formulations ($Rocephin{\circledR}$ ; Roche, and Triaxone ; Hanmi0, the HPLC analytical method for the analysis of ceftriaxone in plasma was used. Fourteen healthy volunteers completed the study and each subject were IM in jected signle doses (1 g) of the test and the reference formulations in a two-way crossover design with an one week drug free interval between doses. Following each administration, plasma concentrations of ceftrixone were monitored over a period of 24 h. Bioequivalence parameters $AUC_{24th}, {\;}T_{max}, {\;}C_{max}$ and MRT determined from the data obtained for the two formulations were examined by analyses of variance (ANOVA) and other criteria and tests for bioequivalence. Results of ANOVA and confidence limits of test/reference ratios of $AUC_{24th}, {\;}T_{max}, {\;}C_{max}$ and MRT, and statistical tests indicated the bioequivalence of the two formulations (i.e., test/reference ratio was within $100{\pm}20%$) except for $T_{max}$ The mean of $T_{max}$ showed only 6. 9% difference from the reference but the detection limit was 22.5% which is slightly over the 20% criteria. No pharmacokinetic parameters including Ka, Kel, Vd and Cl indicated significant difference in between the two fomulations. It was concluded that the data yielded fro the two cefriaxone formulations demonstrated that they were bioequivalent.

• 대한수의학회지
• /
• 제53권2호
• /
• pp.77-82
• /
• 2013

The present study was planned to evaluate the bioequivalence of two commercial formulations of enrofloxacin, which have been marketed as 10% injectable solution after intramuscular administration at a single dose of 2.5 mg/kg body weight to 12 clinically healthy goats The study was carried out on the basis of crossover design. The two formulations were: Baytril as a reference product and Spectrama Vet as a test product. The plasma concentrations of enrofloxacin were measured by high performance liquid chromatography (HPLC) with UV detector. The pharmacokinetics of that data was performed using non-compartmental analysis. The maximum plasma concentration ($C_{max}$), time to reach peak concentration ($T_{max}$), area under concentration-time curve (AUC), elimination half-life ($t_{0.5el}$) were 1.14 and $1.05{\mu}g/mL$, 0.79 and 0.83 h, 5.70 and $5.79{\mu}g.h/mL$, 5.19 and 5.39 h for Baytril and Spectrama Vet, respectively. The 90% confidence interval for the mean ratio of $T_{max}$, $C_{max}$ and AUC were 94.72-116.2, 87.88-97.16 and 86.44-118.72%, respectively. These values falls within the European Medicines Agency bioequivalence acceptance range of 80-125% for both $T_{max}$ and AUC and between 75-133% for $C_{max}$. In conclusion, Spectrama-Vet is bioequivalent to Baytril and both products can be used as interchangeable drug in veterinary medicine practice.

• 한국지반환경공학회 논문집
• /
• 제13권4호
• /
• pp.37-44
• /
• 2012

본 연구는 모래, HAP, Zeolite, 혼합여재에 의한 비점오염원 흡착 반응을 조사하였다. 오수에 대한 모래, HAP, Zeolite와 혼합여재의 흡착은 연속적인 회분식 실험을 통해 조사하였다. 회분식 실험 후 COD, T-N, T-P를 통하여 분석하였다. kinetic model은 유사 1차반응을 통해 분석하였다. Langmuir와 Freundlich isotherm model을 사용하여 적용성을 조사하였다. COD 최대흡착량$(Q_{max})$의 값은 각각 모래 0.0511mg/g, HAP 0.1905mg/g, Zeolite 1.0366mg/g, Mixed media 0.7444mg/g T-N 최대흡착량$(Q_{max})$의 값은 각각 모래 0.0159mg/g, HAP 0.0537mg/g, Zeolite 0.5496mg/g, Mixed media 0.1374mg/g T-P 최대흡착량$(Q_{max})$의 값은 각각 모래 0.0202mg/g, HAP 0.1342mg/g, Zeolite 0.0462mg/g, Mixed media 0.1180mg/g 나타났다. 결과적으로 혼합여재는 비점오염원을 효과적으로 제거하였다.

• 한국임상약학회지
• /
• 제10권1호
• /
• pp.25-29
• /
• 2000

Bioequivalence of cisapride-containing $Cisaplus^{(R)}$ tablets (Daewoong Co.) to reference $Prepulsid^{(R)}$ tablets (Janssen Co.) was evaluated according to the guidelines of Korea Food and Drug Administration (KFDA). Sixteen healthy volunteers were divided randomly into two groups and administered orally at a cisapride dose of 10 mg in a $2\times2$ crossover design. There was a 1-week washout period between the treatments. Blood samples were taken at predetermined time intervals for 48 hr and the plasma cisapride concentrations were determined by an HPLC with UV detector. The area under the plasma drug concentration-time curve (AUC) was caltulated from time zero to the last sampling time by a linear trapezoidal method. The maximum observed plasma drug concentration ($C_{max}$) and the time to $C_{max}\;(T_{max})$ were estimated directly from the drug concentration-time data. Analysis of variance (ANOVA) showed that the apparent differences for AUC, $C_{max}\;and\;T_{max}$ were $-7.52\%,\;-8.91\%\;and\;-15.55\%$, respectively. The minimum detectable differences for AUC, $C_{max}\;and\;T_{max}$ between formulations were $14.52\%,\;11.57\%\;and\;28.00\%$ respectively, at $\alpha=0.05\;and\;1-\beta=0.8\;levels.\;The\;90\%$ confidence intervals for AUC, $C_{max}\;and\;T_{max}\;were\;-16.00\sim0.97\%,\;-15.67\sim-2.15\%\;and\;-31.88\%\sim0.84\%$, respectively. These results satisfy the bioequivalence criteria of KFDA guidelines, indicating that the two formulations of cisapride are bioequivalent.

• Progress in Superconductivity
• /
• 제9권1호
• /
• pp.111-114
• /
• 2007

We have investigated the effect of different heat treatment processes on electrical and magnetic properties of Bi2212/Ag ROSAT wire. The ROSAT wire was fabricated by stacking and arranging 12 filaments Bi2212/Ag tapes in triple rotation symmetry in a Ag tube. ROSAT wires have been prepared using a partial melting method with changing $T_{max}$ and $T_a$ in oxygen atmosphere. The highest critical current density($J_c$) at 65 K under 0 T was $21,158\;A/cm^2$ for wire prepared $890\;^{\circ}C(T_{max})$ and $840\;^{\circ}C(T_a)$, respectively. SEM results indicated that the wire prepared at $890\;^{\circ}C(T_{max})$ and $840\;^{\circ}C(T_a)$ showed better directional phases than the other samples. However the result of magnetic susceptibility measurement indicates that the wire prepared $890\;^{\circ}C(T_{max})$ and $835\;^{\circ}C(T_a)$ had better superconducting phases than the other samples. It was revealed that heat treatment temperature was important factor for superconducting properties of the ROSAT wire.

• 천문학회보
• /
• 제31권2호
• /
• pp.48.1-48.1
• /
• 2006